Can you stay on Wegovy forever — or is there a time limit?

What happens to your weight if you stop Wegovy?

The STEP 1 extension study is the clearest data we have. Participants who stopped semaglutide after 68 weeks regained, on average, around two-thirds of the weight they had lost within a year of stopping, alongside a return of the cardiometabolic improvements the medicine had produced. This isn't a failure of willpower. Semaglutide works by reducing appetite signals and slowing gastric emptying; once those signals are no longer dampened, hunger returns roughly to where it was before treatment began.

That pattern is consistent with how obesity itself is understood clinically: as a chronic condition driven in large part by biology, not behaviour alone. A medicine that addresses that biology tends to need to stay in place, much like blood-pressure treatment isn't considered a fixed course. The STEP 1 trial published in the New England Journal of Medicine remains the most cited evidence base for semaglutide 2.4mg outcomes, and its extension data reinforced exactly this point about durability depending on continuation.

None of this means everyone must stay on Wegovy indefinitely. Some people reach a stable weight, make lasting changes to how they eat and move, and are able to reduce or stop under clinical guidance without full regain. If you're thinking through what long-term use actually involves, our page on whether you can be on Wegovy forever walks through the question in practical terms. But ultimately it's a clinical conversation, not a rule.

Do you have to stay on Wegovy forever if you use it privately?

Not automatically. The licensed indication carries no fixed maximum duration for private prescribing, unlike the NHS route. Under NICE's appraisal of semaglutide (TA875), NHS specialist services are guided to use it for a maximum of two years and to consider stopping if a patient loses less than 5% of body weight after six months at the maintenance dose. That two-year cap applies specifically to the NHS commissioning pathway, within specialist weight management services.

Private treatment is governed by the medicine's SmPC and by the prescriber's ongoing clinical assessment. There's no regulatory cut-off that says a private patient must stop after a set period, but that doesn't mean repeat prescriptions are issued indefinitely without review. A responsible prescriber reassesses at every repeat: is the medicine still working, still tolerated, still appropriate given any changes in health? Our clinical team's approach to whether ongoing treatment is appropriate is always assessed individually, not assumed.

If you're weighing up the ongoing cost and commitment, our Wegovy cost comparison page sets out what to look for in transparent private pricing.

Is staying on semaglutide long-term safe?

The safety profile of semaglutide 2.4mg has been studied across trials lasting up to 104 weeks, and the medicine now has a meaningful real-world record since wider licensing. The most common side effects are gastrointestinal (nausea, loose stools, constipation, reflux) and for most people these are most pronounced early in treatment or after dose increases, settling as the body adjusts. Serious side effects are infrequent but real: in January 2026 the MHRA issued a Drug Safety Update highlighting acute pancreatitis as a known risk requiring awareness, particularly of severe abdominal pain that reaches through to the back.

Long-term, the question of safety is the same as with any ongoing medicine: regular review, monitoring for any new conditions, and honest reporting of symptoms. That's one reason a prescriber checks in before every repeat rather than setting an automatic renewal. The NHS England guidance on weight management injections also notes specific considerations for people starting hormonal contraception or HRT alongside treatment, worth discussing at any clinical review. If you're unsure about a symptom, the MHRA's Yellow Card reporting service is open to patients and carers directly.

For a fuller picture of how long people tend to use it and what the research says about stopping and restarting, the dedicated page on how long Wegovy can be taken covers the question in more depth.

What affects whether you should keep going, or stop?

A few practical factors shape the conversation with your prescriber. Progress matters most: ongoing, meaningful weight loss or successful maintenance of a significant loss generally supports continuing. Tolerability is the other side of that, if side effects remain disruptive months into treatment, the benefit-risk balance shifts. Changes in your overall health picture (new diagnoses, pregnancy, surgery) can also change what's appropriate.

Timing plays a role too. Someone who starts treatment in January, loses good ground, then hits a plateau in summer may have a very different conversation from someone reviewing options in, say, October after several months at a stable weight. There's no single right answer. The question of whether you have to keep taking Wegovy really depends on what you're trying to protect: the weight lost, the health improvements, or both.

Semaglutide as a medicine class, including its role in weight management beyond Wegovy specifically, is explained on our semaglutide information page. If you're considering treatment or a transfer from another provider, a free consultation with our prescribers is the right starting point, they can assess your situation properly rather than give a generic answer.